SEC Filing Summary: Hemispherx Biopharma, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Hemispherx Biopharma, Inc. (not AIM Immunotech Inc.) on March 7, 2011, reporting events occurring on March 3, 2011. The registrant is a Delaware corporation headquartered in Philadelphia, Pennsylvania.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation matters.
Material Changes and Executive Actions
- Executive Bonus: The Compensation Committee awarded a $25,000 extraordinary bonus to Charles T. Bernhardt (CFO and Chief Accounting Officer) for success in financial management and regulatory compliance. The text notes this award was made on March 3, 2010, though reported in this 2011 filing.
- Stock Option Grants: The Board approved the issuance of stock options to William A. Carter (CEO) and David R. Strayer (Medical Director).
- Option Details: Each executive received 10-year options to purchase up to 10,000 shares of common stock under the 2009 Equity Incentive Plan.
- Replacement of Expired Options: These new options replace an identical number of options that expired on January 3, 2011, under the 1990 Stock Option Plan.
- Exercise Price: The exercise price for the replacement options is $4.03 per share, matching the expired options.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, specific risk factors, or contingencies beyond the standard regulatory context of the 8-K form.
Key Facts for Investor Verification
- Verify the discrepancy in the bonus date for Charles T. Bernhardt (stated as March 3, 2010, in a March 2011 filing).
- Confirm the total number of shares authorized under the 2009 Equity Incentive Plan to assess dilution impact.
- Review the company's current stock price relative to the $4.03 exercise price to determine if the new options are in-the-money.
- Check subsequent filings for any financial performance data, as this 8-K contains no operational or financial results.